Osteonecrosis of the Jaw

Categories: Bone diseases, Oral diseases, Rare diseases

Aliases & Classifications for Osteonecrosis of the Jaw

MalaCards integrated aliases for Osteonecrosis of the Jaw:

Name: Osteonecrosis of the Jaw 58


Orphanet: 58  
Rare systemic and rhumatological diseases
Rare bone diseases

External Ids:

ICD10 via Orphanet 33 K10.2
UMLS via Orphanet 72 C2711248
Orphanet 58 ORPHA399293

Summaries for Osteonecrosis of the Jaw

MalaCards based summary : Osteonecrosis of the Jaw is related to osteonecrosis and periodontitis. An important gene associated with Osteonecrosis of the Jaw is CYP2C8 (Cytochrome P450 Family 2 Subfamily C Member 8), and among its related pathways/superpathways are Innate Immune System and Allograft rejection. The drugs Hormones and Zoledronic Acid have been mentioned in the context of this disorder. Affiliated tissues include bone, breast and prostate, and related phenotype is renal/urinary system.

Wikipedia : 74 Osteonecrosis of the jaw (ONJ) is a severe bone disease (osteonecrosis) that affects the jaws (the... more...

Related Diseases for Osteonecrosis of the Jaw

Diseases related to Osteonecrosis of the Jaw via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 221)
# Related Disease Score Top Affiliating Genes
1 osteonecrosis 32.7 VEGFA FDPS CYP2C8
2 periodontitis 31.2 IL17A DEFB4A DEFB1
3 myeloma, multiple 30.6 VEGFA SIRT1 IL17A FDPS
4 bone inflammation disease 30.3 VEGFA IL17A HLA-DRB1
5 osteoporosis 29.9 VEGFA TGFB1 SIRT1 IL17A FDPS CYP19A1
6 bacterial infectious disease 29.8 IL17A DEFB4A DEFB103B DEFB1
7 arthritis 29.0 VEGFA TGFB1 IL17A HLA-DRB1 HLA-DQB1
8 rheumatoid arthritis 29.0 VEGFA TGFB1 IL17A HLA-DRB1 HLA-DQB1
9 inflammatory bowel disease 28.6 VEGFA TGFB1 IL17A HLA-DRB1 HLA-DQB1 DEFB4A
10 diabetes mellitus 28.2 VEGFA TGFB1 SIRT1 IL17A HLA-DRB1 HLA-DQB1
11 gnathodiaphyseal dysplasia 11.3
12 bone disease 11.0
13 bone mineral density quantitative trait locus 8 10.9
14 bone mineral density quantitative trait locus 15 10.9
15 bone resorption disease 10.9
16 osteomyelitis 10.8
17 mammary paget's disease 10.8
18 rapidly involuting congenital hemangioma 10.7
19 renal cell carcinoma, nonpapillary 10.5
20 triiodothyronine receptor auxiliary protein 10.4
21 bone cancer 10.4
22 endosteal hyperostosis, autosomal dominant 10.4
23 avascular necrosis 10.4
24 hypopyon 10.4 VEGFA IL17A
25 mycetoma 10.4 IL17A CYP19A1
26 maxillary sinusitis 10.4
27 kidney cancer 10.4
28 corneal abscess 10.3 DEFB4A DEFB1
29 juvenile nasopharyngeal angiofibroma 10.3 VEGFA CYP19A1
30 brittle bone disorder 10.3
31 mucositis 10.3
32 paget's disease of bone 10.3
33 breast cancer 10.3
34 thrombophilia 10.3
35 actinomycosis 10.3
36 47,xyy 10.3
37 anal fistula 10.3 DEFB4A DEFB103B
38 lymphoproliferative syndrome 10.2
39 fibrous dysplasia 10.2
40 rickets 10.2
41 osteopetrosis 10.2
42 fasciitis 10.2
43 necrotizing fasciitis 10.2
44 ischemic bone disease 10.2 VEGFA FDPS CYP2C8
45 candidiasis 10.2 IL17A DEFB4A DEFB1
46 chorioretinitis 10.2 VEGFA IL17A
47 limbic encephalitis with lgi1 antibodies 10.2 HLA-DRB1 HLA-DQB1
48 aggressive periodontitis 10.2 IL17A DEFB4A DEFB1
49 autoimmune polyglandular syndrome type 3 10.2 HLA-DRB1 HLA-DQB1
50 prostate cancer 10.2

Graphical network of the top 20 diseases related to Osteonecrosis of the Jaw:

Diseases related to Osteonecrosis of the Jaw

Symptoms & Phenotypes for Osteonecrosis of the Jaw

MGI Mouse Phenotypes related to Osteonecrosis of the Jaw:

# Description MGI Source Accession Score Top Affiliating Genes
1 renal/urinary system MP:0005367 9.17 CYP19A1 HLA-DQB1 IL17A SEMA4D SIRT1 TGFB1

Drugs & Therapeutics for Osteonecrosis of the Jaw

Drugs for Osteonecrosis of the Jaw (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Hormones Phase 4
Zoledronic Acid Approved Phase 3 118072-93-8 68740
Denosumab Approved Phase 3 615258-40-7
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
7 Tocotrienol Investigational Phase 3 6829-55-6
8 Ibandronic Acid Phase 3
9 Tocopherols Phase 3
10 Tocotrienols Phase 3
11 Micronutrients Phase 3
12 Vitamins Phase 3
13 Trace Elements Phase 3
14 Free Radical Scavengers Phase 3
15 Antioxidants Phase 3
16 Platelet Aggregation Inhibitors Phase 3
17 Nutrients Phase 3
18 Vasodilator Agents Phase 3
19 Protective Agents Phase 3
20 Phosphodiesterase Inhibitors Phase 3
21 Radiation-Protective Agents Phase 3
22 Mitogens Phase 2, Phase 3
Alendronate Approved Phase 1, Phase 2 121268-17-5, 66376-36-1 2088
24 Antibodies, Monoclonal Phase 1, Phase 2
25 Immunoglobulins Phase 1, Phase 2
26 Antibodies Phase 1, Phase 2
27 Pharmaceutical Solutions Phase 2
Clavulanate Approved, Vet_approved 58001-44-8 5280980
Amoxicillin Approved, Vet_approved 26787-78-0 33613
Clindamycin Approved, Vet_approved 18323-44-9 29029
Phenytoin Approved, Vet_approved 57-41-0 1775
Tetracycline Approved, Vet_approved 60-54-8 5353990
Miconazole Approved, Investigational, Vet_approved 22916-47-8 4189
Teriparatide Approved, Investigational 52232-67-4 16133850
Parathyroid hormone Approved, Investigational 9002-64-6
Pamidronate Approved 40391-99-9 4674
Etidronic acid Approved 2809-21-4, 7414-83-7 3305
tiludronate Approved, Investigational, Vet_approved 89987-06-4 60937
Risedronate Approved, Investigational 105462-24-6 5245
Vitamin D3 Approved, Nutraceutical 67-97-0 6221 5280795
41 Antitubercular Agents
42 Amoxicillin-Potassium Clavulanate Combination
43 Clindamycin palmitate
44 beta-Lactamase Inhibitors
45 Clindamycin phosphate
46 Sodium Channel Blockers
47 Anticonvulsants
48 Diuretics, Potassium Sparing
49 Tin Fluorides
50 Diphosphonates

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
2 Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate in the Treatment of Breast Cancer Patients With Bone Metastases Unknown status NCT00326820 Phase 3 ibandronate sodium;zoledronic acid;Zolendronic Acid
3 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
4 Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks - A Non-Inferiority Phase III Trial Recruiting NCT02051218 Phase 3 Denosumab (reduced dosing);Denosumab (standard dosing)
5 Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ): A Prospective, Randomized Controlled Trial to Evaluate a Novel Non-operative Treatment Recruiting NCT03040778 Phase 3 Pentoxifylline;Placebo;Tocopherol
6 Plasma Rich in Growth Factors for Treatment of Medication Related Osteonecrosis of the Jaw: a Multicenter, Randomized, Clinical Trial Not yet recruiting NCT03390777 Phase 2, Phase 3
7 Denosumab (A Monoclonal Antibody to Receptor Activator of Nuclear Factor-Kappa B Ligand (RANKL) in Crohn's Disease Completed NCT02321280 Phase 1, Phase 2 Denosumab
8 Reduced Dose-density of Denosumab for Maintenance Therapy of Unresectable Giant Cell Tumor of Bone: a Multicenter Phase II Study "REDUCE" Recruiting NCT03620149 Phase 2 Denosumab 120 MG/1.7 ML Subcutaneous Solution [XGEVA]
9 Evaluation of Topical Application of Alendronate Sodium In-situ Gel and Recombinant Human Bone Morphogenic Protein 2 on Dental Implant Stability and Crestal Bone Level: A Randomized Controlled Clinical Study Enrolling by invitation NCT04140006 Phase 1, Phase 2 ALN Gel;BMP Gel;Mixed Gel;Control
10 Phase I Clinical Trial of Use of Autologous Bone Marrow Stem Cells Seeded on Porous Tricalcium Phosphate Matrix and Demineralized Bone Matrix in Patients With Osteonecrosis (MSC/ONM) Unknown status NCT02566681 Phase 1
11 Effect of Denosumab in Reversing Periprosthetic Bone Loss Following Hip Replacement Unknown status NCT02444585 Phase 1 Denosumab
12 Randomized Controlled Trial of Hyperbaric Oxygen in Patients Who Have Taken Bisphosphonates Completed NCT00462098 Phase 1
13 Performance Evaluation of the Micromedic BRONJ Risk Assessment in Vitro Diagnostic Assay. Unknown status NCT02218554
14 Prospective Randomized Clinical Study: Role of Platelet Rich Fibrin (PRF) in the Tooth Extraction Site in the Prevention of Jaw Osteonecrosis on Patients Under Bisphosphonates Therapy Unknown status NCT02198001 tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)
15 Changes in Biochemical Markers of Bone Turnover (Serum CTX and PlNP) After Initiation of a "Drug Holiday" From Bisphosphonates Unknown status NCT02575157
16 A Non-interventional Pharmacovigilance Study of Osteonecrosis of the Jaw and Infection Leading to Hospitalization Among Patients With Cancer Treated With XGEVA™ or Zoledronic Acid in Sweden, Denmark, and Norway Completed NCT01967160
17 Efficacy and Safety on the Use of Bisphosphonates in Paediatrics Completed NCT04012320
18 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer Completed NCT01325142
19 Trans-PBRN Case-control Study of Osteonecrosis of the Jaws Completed NCT01130389
20 S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment Completed NCT00874211
21 Retrospective Cohort Study of ONJ Completed NCT01201330
22 Survey of Oncology Practitioners Prescribing XGEVA® in Europe to Evaluate Their Knowledge of XGEVA® Summary of Product Characteristics Pertaining to Osteonecrosis of the Jaw Completed NCT01998607
23 Genetic Risk of Osteonecrosis of the Jaw (ONJ) in Patients With Metastatic Cancer: Concordance Study Completed NCT00858585
24 Bisphosphonate-Associated Jaw Osteonecrosis and PET Imaging Completed NCT00592982
25 Does Topical Phenytoin Enhance Healing Process in Bisphosphonate-related Osteonecrosis of the Mandible. A Uni-blind Clinical Trial Study Completed NCT03269214 Topical Phenytoin 5%
26 Predictive Value of Bone Turnover Markers During Discontinuation With Alendronate Completed NCT03051620 Discontinue alendronate
27 Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic Castration Resistant Prostate Cancer Completed NCT01062503 Zoledronic acid
28 International, Multicenter, Prospective Registry to Collect Data of Treatment Patterns of Patients With Medication-related Osteonecrosis of the Jaw (MRONJ) and Their Outcome Recruiting NCT02932501
29 Biomarker Identification in Orthopaedic and Oral Maxillofacial Subjects Recruiting NCT01875458
30 Prospective Registry of Prosthodontic Rehabilitation in Oncology Patients Undergoing Jaw Reconstruction Recruiting NCT02661139
31 The Oral Microbiome as a Prognostic Tool in Oral Malignant and Premalignant Lesions and in Medication Related Osteonecrosis of the Jaw Recruiting NCT03418454
32 Does Hyperbaric Oxygen Therapy (HBOT) Reduce Pain, Improve Depression and Impact on Patients' Quality of Life for Those Suffering From Late Radiation Tissue Injury? Recruiting NCT02425215
33 The Effects of Bovine Colostrum in Bone Metabolism in Humans Recruiting NCT04040010
34 Osteonecrosis of the Jaw (ONJ) Case Registry Active, not recruiting NCT01666106

Search NIH Clinical Center for Osteonecrosis of the Jaw

Genetic Tests for Osteonecrosis of the Jaw

Anatomical Context for Osteonecrosis of the Jaw

MalaCards organs/tissues related to Osteonecrosis of the Jaw:

Bone, Breast, Prostate, Lung, T Cells, Bone Marrow, Endothelial

Publications for Osteonecrosis of the Jaw

Articles related to Osteonecrosis of the Jaw:

(show top 50) (show all 2166)
# Title Authors PMID Year
Medication-Related Osteonecrosis of the Jaw-Comparison of Bone Imaging Using Ultrashort Echo-Time Magnetic Resonance Imaging and Cone-Beam Computed Tomography. 61
31688157 2020
Can children be affected by bisphosphonate-related osteonecrosis of the jaw? A systematic review. 61
31447218 2020
Changes in serological bone turnover markers in bisphosphonate induced osteonecrosis of the jaws: A case control study. 61
32031088 2020
The use of Platelet-rich Fibrin in the management of medication-related osteonecrosis of the jaw: A case series. 61
30794883 2020
Use of a xenogeneic collagen matrix on extraction sockets: a new approach in ARONJ prevention (in german) 61
32031353 2020
Comment on "Resolution without surgery of an advanced stage of medication-related osteonecrosis of the jaw (MRONJ) in a patient who could not suspend her treatment for osteoporosis", by Sarmiento (2019). 61
31277903 2020
Histologic analysis of medication-related osteonecrosis of the jaw compared with antiresorptive-exposed bone and other infectious, inflammatory, and necrotic jaw diseases. 61
31606424 2020
The feasibility of locating the affected bone of BRONJ with Indocyanine green. 61
32031311 2020
Awareness About Medication-Related Osteonecrosis of the Jaw Among Dental Professionals: A Multicentre Study. 61
32016175 2020
Medication-related osteonecrosis of the jaw. Implant presence-triggered osteonecrosis: Case series and literature review. 61
31035023 2020
Tc-99m hydroxymethylene diphosphonate SPECT/CT for the evaluation of osteonecrosis of the jaw: preliminary study on diagnostic ability of maximum standardised uptake value. 61
31699430 2020
Immediate reconstruction of mandibular defect after treatment of medication-related osteonecrosis of the jaw (MRONJ) with rhBMP-2/ACS and miniplate: Review of 3 cases. 61
31790947 2020
Saliva diagnostics in patients suffering from bisphosphonate-associated osteonecrosis of the jaw: Results of an observational study. 61
31987715 2020
Role of dendritic cell-mediated immune response in oral homeostasis: A new mechanism of osteonecrosis of the jaw. 61
31919918 2020
Osteonecrosis and osteomyelitis of the jaw associated with tumour necrosis factor-alpha (TNF-α) inhibitors: a systematic review. 61
31645276 2020
Primary wound closure and perioperative antibiotic therapy for prevention of bisphosphonate-related osteonecrosis of the jaw after tooth extraction. 61
32020132 2020
Modified Submental Island Flap for the Surgical Treatment of 4 Patients With Stage 3 Medication-Related Osteonecrosis of the Mandible. 61
31600490 2020
The effects of different doses of teriparatide on bisphosphonate-related osteonecrosis of the jaw in mice. 61
31903673 2020
Effectiveness of laser-assisted treatments for medication-related osteonecrosis of the jaw: a systematic review. 61
31926767 2020
Surgical Treatment of Osteonecrosis of the Jaw: An Emerging Problem in the Era of Bisphosphonates. 61
32004467 2020
Review and update on drugs related to the development of osteonecrosis of the jaw. 61
31880288 2020
[A Case of atypical Femoral Fracture after Dosing Denosumab]. 61
32028752 2020
Effects of zoledronic acid and geranylgeraniol on angiogenic gene expression in primary human osteoclasts. 61
31996529 2020
The use of crevicular fluid to assess markers of inflammation and angiogenesis, IL-17 and VEGF, in patients with solid tumors receiving zoledronic acid and/or bevacizumab. 61
31001696 2020
In vitro effects of alendronate on fibroblasts of the human rotator cuff tendon. 61
31926548 2020
Anti-vascular endothelial growth factor antibody monotherapy causes destructive advanced periodontitis in rice rats (Oryzomys palustris). 61
31707108 2020
Quantitative bone scan imaging using BSI and BUV: an approach to evaluate ARONJ early. 61
31705367 2020
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. 61
31806543 2020
Medication-related osteonecrosis (MRONJ) of the mandible and maxilla. 61
31907213 2020
[Basic Studies on the Mechanism, Prevention, and Treatment of Osteonecrosis of the Jaw Induced by Bisphosphonates]. 61
31902887 2020
Drug holiday clinical relevance verification for antiresorptive agents in medication-related osteonecrosis cases of the jaw. 61
31410544 2020
New Frontiers in Osteoporosis Therapy. 61
31509477 2020
Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. 61
31378564 2019
Medication-related osteonecrosis of the jaw-like lesions in rodents: A comprehensive systematic review and meta-analysis. 61
31373407 2019
Antiresorptive drug-related changes of the mandibular bone densitiy in medication-related osteonecrosis of the jaw patients. 61
31530019 2019
The Effect of Platelet-Rich Fibrin Membrane in Surgical Therapy of Medication-Related Osteonecrosis of the Jaw. 61
31945309 2019
Three-dimensional radiologic-pathologic correlation of medication-related osteonecrosis of the jaw using 3D bone SPECT/CT imaging. 61
31287720 2019
Bisphosphonate-induced reactive oxygen species inhibit proliferation and migration of oral fibroblast: A pathogenesis of bisphosphonate-related osteonecrosis of the jaw. 61
31863459 2019
Immediate hyperbaric oxygen after tooth extraction ameliorates bisphosphonate-related osteonecrotic lesion in rats. 61
31257597 2019
Effects of bisphosphonate treatment on mandibular condyle tissues of temporomandibular joint: A stereological study. 61
30978396 2019
Long-term outcomes of prolonged bisphosphonates more than 2 years in bone metastatic breast cancer: risk vs benefit. 61
31823174 2019
Clinical and panoramic radiographic features of osteomyelitis of the jaw: A comparison between antiresorptive medication-related and medication-unrelated conditions. 61
31915614 2019
Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. 61
31704134 2019
Volumetric analysis of MRONJ lesions by semiautomatic segmentation of CBCT images. 61
31673817 2019
Rare adverse effects of bisphosphonate therapy. 61
31567423 2019
Resolution without surgery of an advanced stage of medication-related osteonecrosis of the jaw (MRONJ) in a patient who could not suspend her treatment for osteoporosis. 61
31174983 2019
Computer programme to assess mandibular cortex morphology in cases of medication-related osteonecrosis of the jaw with osteoporosis or bone metastases. 61
31915613 2019
Medication related osteonecrosis of jaw in a leukemia patient undergoing systemic arsenic trioxide therapy: A rare case report. 61
31255529 2019
Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy. 61
31827217 2019
Pharmacoepidemiology and clinical characteristics of medication-related osteonecrosis of the jaw. 61
31403036 2019

Variations for Osteonecrosis of the Jaw

Expression for Osteonecrosis of the Jaw

Search GEO for disease gene expression data for Osteonecrosis of the Jaw.

Pathways for Osteonecrosis of the Jaw

GO Terms for Osteonecrosis of the Jaw

Cellular components related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.5 VEGFA TGFB1 SEMA4D IL17A DEFB4A DEFB103B
2 MHC class II protein complex GO:0042613 9.16 HLA-DRB1 HLA-DQB1
3 Golgi lumen GO:0005796 8.92 TGFB1 DEFB4A DEFB103B DEFB1

Biological processes related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.76 VEGFA TGFB1 SIRT1 RBMS3
2 defense response GO:0006952 9.74 DEFB4A DEFB103B DEFB1
3 defense response to Gram-positive bacterium GO:0050830 9.7 DEFB4A DEFB103B DEFB1
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.67 VEGFA TGFB1 SEMA4D
5 defense response to Gram-negative bacterium GO:0050829 9.65 DEFB4A DEFB103B DEFB1
6 macrophage differentiation GO:0030225 9.56 VEGFA SIRT1
7 positive regulation of protein phosphorylation GO:0001934 9.56 VEGFA TGFB1 SIRT1 SEMA4D
8 positive regulation of branching involved in ureteric bud morphogenesis GO:0090190 9.55 VEGFA TGFB1
9 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.54 HLA-DRB1 HLA-DQB1
10 antimicrobial humoral response GO:0019730 9.54 DEFB4A DEFB103B DEFB1
11 positive regulation of vascular permeability GO:0043117 9.51 VEGFA TGFB1
12 positive chemotaxis GO:0050918 9.5 VEGFA DEFB4A DEFB103B
13 positive regulation of smooth muscle cell differentiation GO:0051152 9.43 TGFB1 SIRT1
14 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.4 HLA-DRB1 HLA-DQB1
15 positive regulation of blood vessel endothelial cell migration GO:0043536 9.33 VEGFA TGFB1 SIRT1
16 immune response GO:0006955 9.1 SEMA4D IL17A HLA-DRB1 HLA-DQB1 DEFB4A DEFB1
17 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 8.96 HLA-DRB1 HLA-DQB1

Molecular functions related to Osteonecrosis of the Jaw according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II receptor activity GO:0032395 9.16 HLA-DRB1 HLA-DQB1
2 chemoattractant activity GO:0042056 9.13 VEGFA DEFB4A DEFB103B
3 CCR6 chemokine receptor binding GO:0031731 8.8 DEFB4A DEFB103B DEFB1

Sources for Osteonecrosis of the Jaw

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....